Achieve Life Sciences is focused on addressing nicotine dependence through its innovative treatment, cytisinicline, which is derived from natural sources. This compound acts as a partial agonist at nicotine receptors, effectively reducing withdrawal symptoms and cravings associated with smoking and vaping. By binding to the same receptors as nicotine, cytisinicline helps to mitigate the satisfaction derived from smoking, thereby assisting individuals in their efforts to quit. Clinical trials have demonstrated its efficacy, with high compliance rates among participants, indicating its potential as a viable alternative to existing smoking cessation treatments.

The company is advancing cytisinicline through its ORCA (Ongoing Research of Cytisinicline for Addiction) program, which encompasses multiple clinical trials aimed at evaluating its effectiveness for both smoking and vaping cessation. Achieve Life Sciences is committed to making this treatment widely available, as current options for nicotine addiction are limited and have not seen significant innovation in recent years. The focus on cytisinicline represents a promising step forward in the fight against nicotine addiction, addressing a critical public health issue that continues to affect millions.

United States

Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.

Central Nervous System (CNS)

Psychological Diseases

Achieve Life Sciences

Smoking cessation

<p class="font_7">Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of withdrawal symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine addiction and has not been approved by the Food and Drug Administration for any indication in the United States.</p>

Achieve Life Sciences

Company Details